Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

BACKGROUND: Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ fourth-line advanced GIST. Here, we report prespecified analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Schöffski, Patrick, George, Suzanne, Heinrich, Michael C., Zalcberg, John R., Bauer, Sebastian, Gelderblom, Hans, Serrano, César, Jones, Robin L., Attia, Steven, D’Amato, Gina, Chi, Ping, Reichardt, Peter, Becker, Claus, Shi, Kelvin, Meade, Julie, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746146/
https://www.ncbi.nlm.nih.gov/pubmed/36514034
http://dx.doi.org/10.1186/s12885-022-10379-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746146/
https://www.ncbi.nlm.nih.gov/pubmed/36514034
http://dx.doi.org/10.1186/s12885-022-10379-9

Ejemplares similares